NICE nod for Dupixent paves way for first targeted biologic for atopic dermatitis

22 June 2018
2019_biotech_test_vial_discovery_big

English patients who have not responded to at least one other systemic therapy will soon be able to receive routine National Health Service (NHS) prescriptions for a targeted biologic for moderate to severe atopic dermatitis, the most common type of eczema.

Cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has recommended routine use of Sanofi’s (Euronext: SAN) Dupixent (dupilumab), alongside topical corticosteroids, in this indication in a Final Appraisal Determination (FAD).

The NICE recommendation represents a change of heart after the body issued  earlier guidance not backing the treatment, which Sanofi is jointly developing with US biotech Regeneron Pharmaceuticals (Nasdaq: REGN).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology